Catalyst Pharmaceuticals (FRA:CN2) Float Percentage Of Total Shares Outstanding: 94.48% (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CN2 Catalyst Pharmaceuticals Inc FRA:CN2
93 GF Score
Price €27.30
GF Value €20.73
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Catalyst Pharmaceuticals FRA:CN2 93 Float Percentage Of Total Shares Outstanding is 94.48% as of Jul. 22, 2026. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €20.73 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Catalyst Pharmaceuticals's float shares is 115.67 Mil. Catalyst Pharmaceuticals's total shares outstanding is 122.42 Mil. Catalyst Pharmaceuticals's float percentage of total shares outstanding is 94.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Catalyst Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Catalyst Pharmaceuticals's Institutional Ownership is 60.27%.

FRA:CN2
93GF Score
Catalyst Pharmaceuticals Inc FRA:CN2
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catalyst Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Catalyst Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=115.67/122.42
=94.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 94.48% mean?
Catalyst Pharmaceuticals (FRA:CN2) has a Float Percentage Of Total Shares Outstanding of 94.48% as of Jul. 22, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Catalyst Pharmaceuticals and its competitors.
Is Catalyst Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Catalyst Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 94.48%. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to CRNX and NAMS?
Catalyst Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 94.48% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 94.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.73, compared to a current price of €27.30 — trading 31.7% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 94.48%. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current Float Percentage Of Total Shares Outstanding is 94.48% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of €27.30 is trading 31.7% above its estimated GF Value™ of €20.73. GuruFocus considers Catalyst Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:CN2:

  • Float Percentage Of Total Shares Outstanding: 94.48%
  • GF Value™: €20.73 vs. price of €27.30 (31.7% above fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catalyst Pharmaceuticals Business Description

Other Exchanges CPRX:USACN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score

Get the complete analysis for FRA:CN2

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.30
Price
€20.73
GF Value